10-Q: Shoulder Innovations Reports Strong Revenue Growth, IPO Boosts Capital

Shoulder Innovations, Inc. reported a significant increase in net revenue for Q3 2025, driven by higher implant system sales, following its successful Initial Public Offering in August 2025.

Summary

• Net revenue for the three months ended September 30, 2025, increased by $4,302 thousand (57.7%) to $11,756 thousand, compared to $7,454 thousand in the prior year.
• Net revenue for the nine months ended September 30, 2025, increased by $10,003 thousand (43.7%) to $32,901 thousand, compared to $22,898 thousand in the prior year.
• Gross profit for the three months ended September 30, 2025, increased by $3,260 thousand (57.2%) to $8,961 thousand.
• Operating loss for the three months ended September 30, 2025, widened to $(7,641) thousand from $(3,881) thousand in the prior year.
• Net loss for the three months ended September 30, 2025, was $(8,729) thousand, compared to $(4,055) thousand in the prior year.
• Net loss for the nine months ended September 30, 2025, was $(32,587) thousand, compared to $(11,827) thousand in the prior year.
• The company completed its Initial Public Offering (IPO) on August 1, 2025, issuing 5,000,000 shares of common stock at $15.00 per share, generating net proceeds of approximately $64,212 thousand.
• Immediately prior to the IPO, all outstanding convertible preferred stock and $40,000 thousand in convertible notes converted into 15,176,862 shares of common stock.
• Cash, cash equivalents, and marketable securities totaled $137,288 thousand as of September 30, 2025, significantly up from $15,044 thousand at December 31, 2024.
• Implant systems sold increased to 1,584 for the three months ended September 30, 2025, from 1,037 in the same period of 2024.
• The company has an accumulated deficit of $89,628 thousand as of September 30, 2025.
• The Trinity Loan Agreement was amended on July 21, 2025, extending commitment dates for second and third tranches and adjusting the interest rate floor from 11.5% to 11.0%.

Sentiment

Score: 5

Explanation: While the company achieved strong revenue growth and successfully completed its IPO, significantly widening net losses and operating expenses, coupled with a growing accumulated deficit, indicate substantial ongoing investment and a lack of profitability. The strong cash position from the IPO provides a buffer, but the path to profitability remains challenging.

Positives

• Strong net revenue growth: 57.7% for Q3 2025 and 43.7% for the nine months ended September 30, 2025, indicating increasing market penetration and demand for implant systems.
• Successful Initial Public Offering (IPO) on August 1, 2025, raising approximately $64,212 thousand in net proceeds, significantly enhancing the company's capital resources.
• Significant increase in cash, cash equivalents, and marketable securities to $137,288 thousand as of September 30, 2025, providing substantial liquidity for future operations and investments.
• Increase in implant systems sold to 1,584 units in Q3 2025, up from 1,037 units in Q3 2024, demonstrating strong adoption by surgeons and healthcare facilities.
• Amendment of the Trinity Loan Agreement extended commitment dates for future tranches and reduced the interest rate floor from 11.5% to 11.0%, improving debt terms and future financing flexibility.
• CMS approval of total shoulder arthroplasty for reimbursement in Ambulatory Surgery Centers (ASCs) as of January 1, 2024, is expected to continue supporting growth in outpatient settings, a key strategic focus.

Negatives

• Significant increase in operating loss for Q3 2025 to $(7,641) thousand from $(3,881) thousand in Q3 2024, indicating that expense growth is outpacing revenue growth.
• Net loss more than doubled for Q3 2025 to $(8,729) thousand from $(4,055) thousand in Q3 2024, and for the nine months ended September 30, 2025, to $(32,587) thousand from $(11,827) thousand.
• Accumulated deficit grew to $89,628 thousand as of September 30, 2025, from $57,041 thousand at December 31, 2024, reflecting ongoing substantial losses.
• Selling, general and administrative expenses increased substantially by 77.5% in Q3 2025, driven by increased headcount, general corporate costs, commissions, legal costs related to litigation, and public company transition expenses.
• Research and development expenses increased by 39.9% in Q3 2025 due to new product development efforts and external consulting fees, contributing to higher overall expenses.
• Gross margin slightly decreased to 76.2% in Q3 2025 from 76.5% in Q3 2024, primarily due to increased utilization of disposable instruments and an increase to the inventory obsolescence reserve.
• Incurred a $9,952 thousand loss related to the initial issuance of convertible notes in Q3 2025, and an $11,719 thousand expense from the change in fair value of the Series E purchase option for the nine months ended September 30, 2025, significantly impacting the net loss.

Risks

• The company is an early-stage company with a history of significant net losses, expects to incur operating losses in the future, and may not be able to achieve or sustain profitability.
• Failure to manage rapid growth effectively could materially and adversely affect the business.
• The company has a significant amount of debt ($15,000 thousand outstanding under Trinity Loan Agreement), which may affect its ability to operate and secure additional financing in the future.
• Substantial additional funding may be required, which may not be available on acceptable terms, or at all, potentially leading to delays, scaling back, or cessation of innovation efforts or operations.
• The company operates in a very competitive business environment, and inability to compete successfully against existing or potential competitors may adversely affect its business, financial condition, and results of operations.
• Failure to develop and retain an effective commercial organization, or inability to successfully expand it, could negatively impact sales and prevent generation of sufficient net revenue to sustain profitability.
• The business plan relies on certain assumptions about the market for implant systems; the addressable market may be smaller than estimated, or the company may be unable to capture additional market share.
• Business is dependent upon the adoption of implant systems by hospitals, ambulatory surgery centers (ASCs), surgeons, and patients.
• Long-term growth depends on the ability to enhance implant systems, expand indications, and develop and commercialize additional products in a timely manner; failure to innovate could lead to loss of competitiveness.
• The company faces the risk of product liability claims that could be expensive, divert management's attention, harm its reputation and business, and may not be adequately covered by insurance.
• Industry trends have resulted in increased downward pricing pressure on medical services and products, which may affect the ability to sell products at prices necessary to support the current business strategy.
• If hospitals, ASCs, and other health care facilities do not approve the use of implant systems, sales may not increase.
• Dependence on third-party contract manufacturers and suppliers, some of which are single-source, to produce and package all elements of shoulder implant systems; failure to supply could have a material adverse effect.
• Results of operations will be materially harmed if the company is unable to accurately forecast demand for implant systems and manage inventory.
• Inability to continue to successfully demonstrate to shoulder specialists or key opinion leaders the merits of implant systems and technologies compared to competitors may make market acceptance difficult.
• Loss of any member of the executive management team or inability to attract and retain highly skilled members of dedicated commercial leadership and marketing teams, as well as certain third-party engineers, could have a material adverse effect.
• Inability to obtain and maintain significant patent or other intellectual property protection for products, or inadequate scope of protection, could allow competitors to develop and commercialize similar products.
• Devices and operations are subject to extensive government regulation and oversight in the United States; failure to comply with applicable requirements could harm the business.
• Relationships with customers, physicians, and third-party payors are subject to federal and state health care fraud and abuse laws, false claims laws, physician payment transparency laws, and other health care laws and regulations; violations could lead to substantial penalties.
• Rising prices or unavailability of raw materials could adversely affect business and results of operations.
• Performance issues, service interruptions, or price increases by shipping carriers could adversely affect the business and harm its reputation and ability to provide systems on a timely basis.
• If coverage or adequate levels of reimbursement from third-party payors for procedures using implant systems are not obtained or maintained, shoulder specialists and patients may be reluctant to use systems, and the business will suffer.
• The misuse or off-label use of systems may result in injuries that harm patients and lead to product liability suits, harm reputation, or result in costly investigations, fines, or sanctions by regulatory bodies.
• Implant systems and other future products may cause or contribute to adverse medical events or be subject to failures or malfunctions which may be required to be reported to the FDA; failure to do so would be subject to sanctions.
• Disruptions at the FDA and other government agencies caused by funding shortages, staffing limitations, or global health concerns could hinder their ability to review, approve, or commercialize products in a timely manner.
• The company and third parties with whom it works are subject to stringent and evolving U.S. and foreign laws, regulations, and rules, contractual obligations, and industry standards related to data privacy and security; failures to comply could adversely affect the business.
• As an emerging growth company and a smaller reporting company, the reduced reporting requirements may make common stock less attractive to investors.
• Continued increased costs and additional regulations and requirements as a public company could lower profits or make it more difficult to run the business.
• Inability to design, implement, and maintain effective internal control over financial reporting in the future could lead to loss of investor confidence and a decline in stock price.
• The market price of common stock may be volatile, which could result in substantial losses for owners.
• If operating and financial performance in any given period does not meet public guidance, the market price of common stock may decline.
• Principal stockholders and management own a significant percentage of stock and will be able to exert significant control over matters subject to stockholder approval.
• Sales of a substantial number of shares of common stock in the public market could cause the stock price to fall.
• Provisions in charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management.
• Claims for indemnification by directors, officers, and other employees or agents may reduce available funds to satisfy successful third-party claims.
• Exclusive forum provisions in the charter documents could limit stockholders' ability to obtain a favorable judicial forum for disputes.
• Engaging in acquisitions or strategic partnerships may increase capital requirements, dilute stockholders, cause incurrence of debt or contingent liabilities, and subject the company to other risks.
• Unfavorable global and regional economic, political, and health conditions could adversely affect business, financial condition, or results of operations.
• The company or third parties it depends on may be adversely affected by natural disasters and other catastrophic events, and business continuity and disaster recovery plans may not adequately protect from such events.
• The company is subject to risks from legal and arbitration proceedings that may prevent it from pursuing business activities or require it to incur additional costs in defending against claims or paying damages.
• The requirements of being a public company may divert management's attention from growth strategies and other business concerns.
• If securities or industry analysts issue an adverse or misleading opinion regarding the stock, stock price and trading volume could decline.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
• Insurance may not cover all potential losses or liabilities that may arise.
• The company is subject to U.S. anti-bribery, anti-corruption, and anti-money laundering laws, as well as export control, customs laws, economic sanctions, and other trade laws and regulations; violations can face serious consequences.
• The increasing use of social media platforms presents new risks and challenges.
• The ability to use net operating loss carryforwards and certain other tax attributes may be subject to limitation.

Future Outlook

The company expects to continue incurring operating losses for the foreseeable future due to ongoing investments in scaling its business, expanding its commercial organization, increasing general and administrative expenses as a public company, and funding research and development activities. Net revenue is anticipated to increase as the commercial organization expands, new customers are added, sales territories grow, and new products are introduced. The company plans to focus on long-term revenue growth through ecosystem investments, technology improvements, new product development (e.g., fracture-specific, revision, metal-hypersensitivity implants), and expansion into adjacent markets like sports medicine and trauma. Management believes current cash, cash equivalents, marketable securities, and available debt tranches will fund operations and capital expenditures for at least 12 months. Seasonal sales fluctuations, with lower demand in the third calendar quarter, are expected to become more pronounced. Gross margin is projected to remain consistent, while selling, general and administrative, and research and development expenses are expected to increase.

Management Comments

• We are a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market.
• We believe our exclusive focus on shoulder surgical care, combined with a highly specialized commercial organization and strong clinical data, positions us well to capture significant share in this large, growing market.
• We believe the shoulder surgical care market today presents a significant market opportunity.
• We view ourselves as specialists serving specialists, having purposefully built our commercial organization around the unique needs of shoulder surgeons.
• We believe this outsourcing strategy provides the expertise and capacity required to effectively and efficiently scale production based on demand, and helps to ensure low-cost production and a capital efficient business model.
• We have experienced significant growth in recent years, primarily driven by growth in our net revenue from the sale of our advanced implant systems sold.
• We expect to continue to incur losses for the foreseeable future and to expend significant amounts of cash for the foreseeable future as we continue to scale our business, increase selling, general and administrative expenses to support the expansion of our commercial organization and efforts, increase general and administrative expenses to support being a publicly-traded company and invest in research and development activities.
• Based on our current operating plan, we believe that the expected cash generated from the sale of our systems, our existing cash, cash equivalents and marketable securities and amounts under our Trinity Loan Agreement, will be sufficient to fund our planned operating expenses and capital expenditure requirements for at least 12 months from the date hereof.

Industry Context

The company operates in the highly competitive and dynamic shoulder surgical care market, characterized by rapid technological development and product innovation. Industry trends indicate an increasing shift towards outpatient and Ambulatory Surgery Center (ASC) settings for procedures, a trend the company is well-positioned to capitalize on, especially with CMS approval for total shoulder arthroplasty reimbursement in ASCs. The orthopedic industry typically experiences seasonal sales fluctuations, with lower volumes in the third calendar quarter, which the company also anticipates. Broader industry pressures include healthcare cost containment initiatives, leading to increased downward pricing pressure on medical services and products. The medical device industry's interactions with physicians are under heightened scrutiny from government agencies, impacting compliance and medical education programs. The evolving regulatory landscape for AI also presents risks related to data privacy, security, and intellectual property for companies integrating AI solutions.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct comparison to global benchmarks.
• The company competes with large, multinational orthopedic companies such as Arthrex, Enovis, Exectech, Johnson & Johnson, Smith & Nephew, Stryker, and Zimmer Biomet, which generally possess greater financial resources, more established distribution networks, and broader product portfolios.
• The company's gross margin of 76.2% (Q3 2025) and 76.4% (9M 2025) is generally considered strong within the medical device industry, although it experienced a slight year-over-year decrease.
• The company's rapid net revenue growth (57.7% in Q3 2025 and 43.7% in 9M 2025) significantly outpaces typical growth rates for established medical device markets, which are often in the mid-single to low-double digits.
• The substantial operating losses and accumulated deficit are characteristic of an early-stage, high-growth medical technology company heavily investing in research and development and commercial expansion, contrasting with the profitability profiles of more mature industry players.

Corporate Governance

Legal Proceedings

• On February 28, 2024, the Company filed a patent infringement complaint against Catalyst Orthoscience Inc. in United States District Court for the District of Delaware, alleging infringement through Catalyst's reverse shoulder systems.
• On March 20, 2024, Catalyst Orthoscience Inc. filed a counterclaim against the Company in the same court, alleging patent infringement by certain of the Company's products.
• The Company is seeking an injunction, monetary damages, interest, fees, and other costs in its lawsuit.
• The Company believes it has substantial and meritorious defenses to Catalyst's claims and intends to vigorously defend its position.
• The Company is currently unable to determine the likelihood of an outcome or estimate a range of reasonably possible losses for the ongoing litigation.
• No material legal proceedings were terminated, settled, or otherwise resolved during the nine months ended September 30, 2025.

Related Party Transactions

• The company has a software license agreement with Genesis Software Innovations, LLC, where Robert Ball (CEO & Executive Chairman) is a co-founder and director, and Matthew Ahearn (COO & Director) is a director of Genesis Investment Holdings, LLC, an investor in Genesis Software. The agreement requires an upfront payment, an incremental payment upon FDA clearance, and quarterly royalties of 4% of net sales until an aggregate of $7,000 thousand is paid. Payments to Genesis Software were $433 thousand (Q3 2025) and $1,174 thousand (9M 2025) for the license, and $302 thousand (Q3 2025) and $1,326 thousand (9M 2025) for software development. Amounts payable were $445 thousand (Sep 30, 2025) and $276 thousand (Dec 31, 2024).
• The company has a consulting agreement with Genesis Innovation Group, an entity under common ownership where Robert Ball is a co-founder and director. Payments to Genesis Innovation Group were $1,093 thousand (Q3 2025) and $3,388 thousand (9M 2025). Amounts payable were $588 thousand (Sep 30, 2025) and $537 thousand (Dec 31, 2024).
• Robert Ball was an investor in Revelation Medical Devices (RMD) during Q1 2024. The company paid RMD $859 thousand for surgical instruments during the nine months ended September 30, 2024.
• Genesis Investment Holdings, LLC, an affiliate of cultivate(MD) Holdings, LLC (a beneficial owner of >5% of company stock), exercised 988,999 Series Seed warrants on March 4, 2025, resulting in proceeds of $83 thousand.
• In connection with the Trinity Loan Agreement, the company issued a warrant to purchase 87,157 shares of Series D convertible preferred stock to Trinity Capital Inc., which converted to common stock warrants upon IPO completion.

Stakeholder Impact

• Shareholders experienced dilution from the IPO and conversion of preferred stock/convertible notes to common stock, and face potential stock price volatility due to significant losses and market conditions. No dividends are expected in the foreseeable future, with returns dependent on stock price appreciation. The concentration of ownership by principal stockholders and management could influence corporate decisions.
• Employees are impacted by increased headcount in the commercial organization and increased stock-based compensation expense. There is a risk of losing key personnel or difficulty attracting and retaining skilled team members. Employees are also subject to anti-bribery, anti-corruption, and other trade laws, with potential penalties for misconduct.
• Customers (hospitals, ASCs, surgeons, patients) benefit from increased availability of implant systems and continued product development. However, they are dependent on third-party payor reimbursement for procedures and face risks of product liability claims, recalls, or adverse medical events. Shipping issues or supply chain disruptions could lead to delays or cancellations of surgeries.
• Suppliers and contract manufacturers are experiencing increased demand due to company growth but are dependent on the company's ability to accurately forecast demand. They face risks of non-compliance with cGMP requirements and potential supply interruptions if single-source suppliers fail. There is also a risk of intellectual property misuse if not adequately monitored.
• Creditors, particularly Trinity Capital, hold a secured position with substantially all company assets as collateral. The loan agreement covenants limit the company's financial flexibility, and there is a risk of default if covenants are breached. Extended commitment dates for future tranches provide continued financing potential.

Next Steps

• Continue to scale the commercial organization to drive broader awareness, adoption, and demand for implant systems.
• Further expand and utilize the external network of independent distributors to enhance market reach.
• Continue to invest in improving technologies, developing new products (e.g., fracture-specific system, revision solution, implants tailored for metal-hypersensitivity), and expanding cleared indications.
• Strategically pursue entry into certain international markets over time to capture long-term growth opportunities.
• Maintain sufficient levels of inventory and instrumentation to meet estimated demand as the business grows.
• Work with payors to ensure positive coverage decisions and payment rates in outpatient settings, leveraging the recent CMS approval for total shoulder arthroplasty in ASCs.
• Evaluate the impact of new accounting standards (ASU 2023-09 and ASU 2024-03) on financial statements and related disclosures.
• Address the single observation regarding inadequate validation of third-party software to address active vulnerability threats identified by the FDA.
• Potentially draw on the second and third tranches of the Trinity Loan Agreement, subject to achieving specified revenue milestones.

Key Dates

Recommendation

Shoulder Innovations demonstrates strong top-line growth and successfully completed its IPO, significantly bolstering its cash position. This provides crucial capital for continued investment in R&D and commercial expansion in a growing market. However, the company's net losses are widening considerably, indicating that current growth is highly expense-driven and profitability remains a distant goal. The reliance on single-source suppliers and ongoing litigation also present notable risks. Given the strong market opportunity and recent capital infusion, but also the significant operational losses and execution risks, a 'hold' recommendation is appropriate. Investors should monitor the company's ability to manage expenses, improve gross margins, and progress towards profitability while continuing to expand market share.

Keywords

Shoulder arthroplasty, Medical technology, Orthopedic implants, SEC filing, 10-Q, IPO, Financial results, Revenue growth, Net loss, Medical devices, Surgical care, Risk factors, Convertible notes, Capital raise, FDA regulation, Intellectual property, Supply chain, Healthcare industry, Ambulatory Surgery Centers, Corporate governance